MIR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2

Cell Death and Disease

Volumn 6, Issue 7, 2015, Pages

  Sheng, L ^a   He, P ^a   Yang, X ^a   Zhou, M ^a   Feng, Q ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MIR 612; PROTEIN KINASE B BETA; UNCLASSIFIED DRUG; AKT2 PROTEIN, HUMAN; MICRORNA; MIRN612 MICRORNA, HUMAN; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TISSUE; CELL COUNTING; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FILTERS AND MEMBRANES; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER METASTASIS; LOSS OF FUNCTION MUTATION; MALE; METASTASIS; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; BIOSYNTHESIS; CARCINOGENESIS; COLORECTAL TUMOR; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR RECURRENCE;

CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84947477287     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.184     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Alwan A. World Health Organization. Disaster Med Public Health Prep 2007; 1: 7-8.
3. Chu E. Colorectal cancer (CRC) continues to be a major public health problem in the United States and throughout the world. Cancer J 2010; 16: 195.
4. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010; 59: 1670-1679.
5. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (SUPPL. 3): iii1-iii9.
6. Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. Biomed Res Int 2014; 2014: 782890.
7. Altobelli E, Lattanzi A, Paduano R, Varassi G, di Orio F. Colorectal cancer prevention in Europe: burden of disease and status of screening programs. Prev Med 2014; 62: 132-141.
8. Andrews L. Dietary flavonoids for the prevention of colorectal cancer. Clin J Oncol Nurs 2013; 17: 671-672.
9. Laurent-Puig P, Agostini J, Maley K. Colorectal oncogenesis. Bull Cancer 2010; 97: 1311-1321.
10. Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev 2013; 14: 2201-2205.
11. Xue J, Niu J, Wu J, Wu ZH. MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol 2014; 5: 730-743.
12. Cheng G. Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 2014; 81: 75-93.
13. Dong Y, Yu J, Ng SS. MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manage Res 2014; 6: 405-422.
14. Zhou JJ, Zheng S, Sun LF, Zheng L. MicroRNA regulation network in colorectal cancer metastasis. World J Biol Chem 2014; 5: 301-307.
15. Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J et al. MicroRNA-31 activates the RAS pathway and functions as an oncogenic microRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem 2013; 288: 9508-9518.
16. Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 2013; 15: 180-191.
17. Balaguer F, Moreira L, Lozano JJ, Link A, Ramirez G, Shen Y et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res 2011; 17: 6239-6249.
18. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K et al. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 2012; 19: 3065-3071.
19. Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010; 9: 2265-2275.
20. Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep 2013; 30: 320-326.
21. Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LX et al. miR-612 suppresses the invasivemetastatic cascade in hepatocellular carcinoma. J Exp Med 2013; 210: 789-803.
22. Tang J, Tao ZH, Wen D, Wan JL, Liu DL, Zhang S et al. miR-612 suppresses the stemness of liver cancer via Wnt/β-catenin signaling. Biochem Biophys Res Commun 2014; 447: 210-215.
23. Sudoyo AW. A biomarker for metastatic colorectal cancer and treatment goals. Acta Med Indones 2014; 46: 81-82.
24. Li N, Tang A, Huang S, Li Z, Li X, Shen S et al. MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway. Mol Cell Biochem 2013; 380: 107-119.
25. Bates RC. Colorectal cancer progression: integrin alphavbeta6 and the epithelialmesenchymal transition (EMT). Cell Cycle 2005; 4: 1350-1352.
26. Bates RC, Mercurio AM. The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 2005; 4: 365-370.
27. Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther 2012; 11: 1166-1173.
28. Zhou Q, Yang M, Lan H, Yu X. miR-30a negatively regulates TGF-beta1-induced epithelialmesenchymal transition and peritoneal fibrosis by targeting Snai1. Am J Pathol 2013; 183: 808-819.
29. Agarwal E, Brattain MG, Chowdhury S. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal 2013; 25: 1711-1719.
30. Kang B, Hao C, Wang H, Zhang J, Xing R, Shao J et al. Evaluation of hepatic-metastasis risk of colorectal cancer upon the protein signature of PI3K/AKT pathway. J Proteome Res 2008; 7: 3507-3515.